Advertisement

Tumor Biology

, Volume 35, Issue 5, pp 4735–4739 | Cite as

The Glu298Asp polymorphism in the NOS3 gene and the risk of prostate cancer

  • Yonggang Zhang
  • Qingyi Jia
  • Qing He
  • Jiani Shen
  • Jiqiao Yang
  • Pei Xue
  • Mengmeng Ma
  • Rui Xu
  • Liang Du
Research Article

Abstract

The Glu298Asp polymorphism in the NOS3 gene has been implicated as a risk factor for prostate cancer. To date, several studies have evaluated the associations between the Glu298Asp polymorphism and prostate cancer risk; however, the results were inconclusive. The aim of the current study was to perform a meta-analysis to investigate the association between the polymorphism and the risk of prostate cancer. A total of 3,206 cases and 3,880 controls from eight case-control studies were included for data synthesis. The overall results suggested no significant association between the polymorphism and the risk of prostate cancer (OR=1.01, 95 % CI=0.92–1.11, p = 0.83 for Asp/Asp+Glu/Asp vs. Glu/Glu). In the stratified analysis according to ethnicity, no significant associations were observed in Asians and Europeans. The current meta-analysis suggested that the Glu298Asp polymorphism of the NOS3 gene might not contribute to the risk of prostate cancer.

Keywords

Prostate cancer Polymorphism NOS3 Meta-analysis 

Notes

Conflict of Interest

None.

References

  1. 1.
    Wei B, Zhou Y, Xu Z, Ruan J, Cheng H, Zhu M, et al. GSTP1 Ile105Val polymorphism and prostate cancer risk: evidence from a meta-analysis. PLoS ONE. 2013;8(8):e71640. doi: 10.1371/journal.pone.0071640.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Teixeira AL, Gomes M, Nogueira A, Azevedo AS, Assis J, Dias F, et al. Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFbeta1 signaling pathway modulation. PLoS ONE. 2013;8(8):e72419. doi: 10.1371/journal.pone.0072419.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ifere GO, Desmond R, Demark-Wahnefried W, Nagy TR. Apolipoprotein E gene polymorphism influences aggressive behavior in prostate cancer cells by deregulating cholesterol homeostasis. Int J Oncol. 2013;43(4):1002–10. doi: 10.3892/ijo.2013.2057.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Brankovic A, Brajuskovic G, Nikolic Z, Vukotic V, Cerovic S, Savic-Pavicevic D, et al. Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population. Int J Exp Pathol. 2013. doi: 10.1111/iep.12045.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, Chen J, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomark Prev: Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2008;17(4):972–7. doi: 10.1158/1055-9965.EPI-07-2787.CrossRefGoogle Scholar
  6. 6.
    Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, et al. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev: Off J Eur Cancer Prev Organ. 2002;11(4):343–50.CrossRefGoogle Scholar
  7. 7.
    Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urol Oncol. 2012. doi: 10.1016/j.urolonc.2012.01.002.PubMedGoogle Scholar
  8. 8.
    Huang J, Yang J, Wang H, Xiong T, Zhang H, Ma Y, et al. The association between the poly(A) polymorphism in the VDR gene and cancer risk: a meta-analysis. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(3):1833–8. doi: 10.1007/s13277-013-0724-0.CrossRefGoogle Scholar
  9. 9.
    Liu C, Yin Q, Hu J, Li L, Zhang Y, Wang Y. A meta-analysis of evidences on XPC polymorphisms and lung cancer susceptibility. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(2):1205–13. doi: 10.1007/s13277-013-0663-9.CrossRefGoogle Scholar
  10. 10.
    Zhang YG, Li XB, Zhang J, Huang J, He C, Tian C, et al. The I/D polymorphism of angiotensin-converting enzyme gene and asthma risk: a meta-analysis. Allergy. 2011;66(2):197–205.CrossRefPubMedGoogle Scholar
  11. 11.
    Lee KM, Kang D, Park SK, Berndt SI, Reding D, Chatterjee N, et al. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis. 2009;30(4):621–5. doi: 10.1093/carcin/bgp028.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Cheng ZG, Zhou W, Tao ZH, Chen W. Associaiton of endothelial nitric oxide cynthase gene polymorphism with prostae cancer. Zhong Guo Nan Ke Xue Za Zhi. 2011;25(7):18–21.Google Scholar
  13. 13.
    Ziaei SA, Samzadeh M, Jamaldini SH, Afshari M, Haghdoost AA, Hasanzad M. Endothelial nitric oxide synthase Glu298Asp polymorphism as a risk factor for prostate cancer. Int J Biol Mark. 2013;28(1):43–8. doi: 10.5301/JBM.2012.9585.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yonggang Zhang
    • 1
  • Qingyi Jia
    • 2
  • Qing He
    • 2
  • Jiani Shen
    • 2
  • Jiqiao Yang
    • 2
  • Pei Xue
    • 2
  • Mengmeng Ma
    • 1
  • Rui Xu
    • 2
  • Liang Du
    • 1
  1. 1.The Periodical Press of West China HospitalSichuan UniversityChengduChina
  2. 2.West China Hospital/West China Medical SchoolSichuan UniversityChengduChina

Personalised recommendations